Cowen and Company reaffirmed their market perform rating on shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) in a report issued on Tuesday, July 25th.
A number of other equities research analysts have also recently weighed in on the company. Maxim Group boosted their price objective on Keryx Biopharmaceuticals from $7.00 to $9.00 and gave the company a buy rating in a research note on Monday, May 15th. ValuEngine cut Keryx Biopharmaceuticals from a hold rating to a sell rating in a research note on Friday, June 2nd. Zacks Investment Research cut Keryx Biopharmaceuticals from a buy rating to a hold rating in a research note on Monday, July 17th. Finally, BidaskClub cut Keryx Biopharmaceuticals from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $7.48.
Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 0.43% during trading on Tuesday, reaching $6.97. 1,224,936 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $7.14 and a 200-day moving average of $6.10. Keryx Biopharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.38. The stock’s market capitalization is $827.69 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.60. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The firm had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.51 million. During the same quarter in the prior year, the firm posted ($0.42) EPS. Keryx Biopharmaceuticals’s quarterly revenue was up 62.4% compared to the same quarter last year. On average, equities research analysts anticipate that Keryx Biopharmaceuticals will post ($1.07) EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. OZ Management LP acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at about $109,000. Usca Ria LLC acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at about $128,000. Jane Street Group LLC acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at about $141,000. Legal & General Group Plc boosted its position in Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the last quarter. Finally, Lincoln Capital Corp boosted its position in Keryx Biopharmaceuticals by 13.1% in the first quarter. Lincoln Capital Corp now owns 30,300 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 3,500 shares during the last quarter. Institutional investors and hedge funds own 62.35% of the company’s stock.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
